FDA novel drug approvals 2025
New molecular entities and new therapeutic biologics approved by FDA's CDER in 2025, from Drugs@FDA records (original applications of submission class Type 1, counted once per active ingredient). Each entry links to its Drugs@FDA record. New approvals can take several days to appear in Drugs@FDA; FDA's own list is Novel Drug Approvals for 2025.
46 novel approvals · Drugs@FDA data as of Oct 13, 2026.
Nereus
tradipitant
Yartemlea
narsoplimab-wuug
Myqorzo
aficamten
Exdensur
depemokimab-ulaa
Cardamyst
etripamil
Lerochol
lerodalcibep-liga
Nuzolvence
zoliflodacin
Voyxact
sibeprenlimab-szsi
Hyrnuo
sevabertinib
Redemplo
plozasiran sodium
Komzifti
ziftomenib
Kygevvi
doxecitine and doxribtimine
Lynkuet
elinzanetant
Jascayd
nerandomilast
Rhapsido
remibrutinib
Inluriyo
imlunestrant tosylate
Palsonify
paltusotine hydrochloride
Forzinity
elamipretide hydrochloride
Keytruda Qlex
pembrolizumab and berahyaluronidase alfa-pmph
Wayrilz
rilzabrutinib
Dawnzera (autoinjector)
donidalorsen sodium
Brinsupri
brensocatib
Hernexeos
zongertinib
Modeyso
dordaviprone hydrochloride
Vizz
aceclidine hydrochloride
Sephience
sepiapterin
Anzupgo
delgocitinib
Ekterly
sebetralstat
Lynozyfic
linvoseltamab-gcpt
Zegfrovy
sunvozertinib
Andembry
garadacimab-gxii
Ibtrozi
taletrectinib adipate
Enflonsia
clesrovimab-cfor
Tryptyr
acoltremon
Emrelis
telisotuzumab vedotin-tllv
Avmapki Fakzynja Co-Pack (copackaged)
avutometinib potassium and defactinib hydrochloride
Imaavy
nipocalimab-aahu
Penpulimab-Kcqx
penpulimab-kcqx
Vanrafia
atrasentan hydrochloride
Qfitlia
fitusiran sodium
Blujepa
gepotidacin mesylate
Romvimza
vimseltinib
Gomekli
mirdametinib
Journavx
suzetrigine
Grafapex
treosulfan
Datroway
datopotamab deruxtecan-dlnk






